Regeneron Pharmaceuticals
Clinical trials sponsored by Regeneron Pharmaceuticals, explained in plain language.
-
New eye drug targets fluid buildup to fight glaucoma
Disease control Not yet recruitingThis study tests an experimental drug called REGN22530 in people with primary open angle glaucoma or ocular hypertension. The drug is designed to block a protein in the eye that causes fluid buildup and high pressure. Researchers are checking for side effects, how the drug moves …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to melt liver fat and stop scarring in MASH patients
Disease control Not yet recruitingThis study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug o…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody drug aims to prevent strokes in irregular heartbeat
Disease control Not yet recruitingThis large phase 3 trial tests an experimental drug, REGN7508, against the standard blood thinner apixaban for preventing strokes in people with atrial fibrillation (an irregular heartbeat). The study will enroll over 15,000 participants to compare how well each drug prevents str…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
Disease control Not yet recruitingThis study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will…
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New obesity drug REGN20934 enters first human safety trial
Disease control Not yet recruitingThis Phase 1 study tests a new drug called REGN20934 in 90 adults who are overweight or obese. The main goal is to check the drug's safety, side effects, and how the body processes it. Participants receive a single dose of either the drug or a placebo, and researchers monitor the…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Immune-Boosting drug combo targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can dupilumab keep COPD patients out of the hospital?
Disease control Not yet recruitingThis study tests whether adding dupilumab to standard COPD treatment can prevent another flare-up or hospital stay within 90 days. About 754 adults who were recently hospitalized for a COPD exacerbation will receive either dupilumab or a placebo. The goal is to see if the drug re…
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug cocktail takes on childhood brain cancers
Disease control Not yet recruitingThis study tests two immunotherapy drugs, fianlimab and cemiplimab, in children and young adults with recurrent high-grade glioma or ependymoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. Participants will receive the drugs before an…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising antibody trial aims to halt rare bone disease in kids
Disease control Not yet recruitingThis Phase 3 trial tests garetosmab, an antibody that blocks activin A, in 18 children and teens with fibrodysplasia ossificans progressiva (FOP), a rare disease where muscle and tissue turn into bone. The study will check safety, side effects, and whether the drug reduces new ab…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Experimental antibodies aim to block cat allergy eye itch
Symptom relief Not yet recruitingThis study tests whether two experimental antibodies, given alone or together, can reduce eye allergy symptoms caused by cat dander. About 570 adults and children aged 8 and older with confirmed cat allergy will receive either the antibodies or a placebo. The main goal is to see …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New drug REGN22044 tested in people for the first time
Knowledge-focused Not yet recruitingThis study is the first time REGN22044 is given to humans. It will enroll 64 healthy adults to check for side effects, measure drug levels in the blood, and see if the body makes antibodies against it. The goal is to gather safety and dosing information, not to treat any disease.
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC